Murtaza Mussaji, DO
Internal Medicine · Houston, TXNPI 1487705034
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $32,030 of the $40,720 with a category attached, or 78.7%. It is spread thinly across 58 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $10,377 and has fallen 55.9% since, to $4,573 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,407 payments — averaging $28.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$8K
- AstraZeneca$7K
- Sanofi-aventis U.S. LLC$4K
- GSK$2K
- Lilly USA, LLC$2K
- Pfizer$1K
- plus $15K from 52 others
Across 1,693 payments — averaging $7729.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2.6M
- AstraZeneca$2.4M
- Pfizer$2.1M
- Modernatx, Inc.$1.3M
- Genentech, Inc.$1M
- Merck$1M
- plus $2.6M from 12 others
What the payments were for
- Consulting fees$8,41421%
- Travel & lodging$1560%
- Food & beverage$32,03079%
- Education$1000%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$2,380
- DISEASE STATE$2,105
- FARXIGA$1,978
- Victoza$1,485
- NURTEC ODT$1,312
- SOLIQUA 100/33$1,101
- ENTRESTO$813
- Ozempic$730
- Kerendia$378
- REZDIFFRA$285
- MOUNJARO$245
- KRYSTEXXA$244
- Wegovy$241
- JARDIANCE$238
- AJOVY$238
- AIRSUPRA$232
- TRELEGY ELLIPTA$227
- BREZTRI$220
- CAPLYTA$128
- ProAir Digihaler$126
How this compares
$40,720 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 730 | $911,832 |
| JardianceEmpagliflozin | 326 | $374,012 |
| FarxigaDapagliflozin Propanediol | 284 | $303,958 |
| TrulicityDulaglutide | 137 | $265,408 |
| EliquisApixaban | 205 | $221,735 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 187 | $217,961 |
| RybelsusSemaglutide | 106 | $197,989 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 158 | $176,947 |
| Xigduo XrDapaglifloz Propaned/Metformin | 157 | $168,842 |
| Tresiba Flextouch U-200Insulin Degludec | 143 | $154,482 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 128 | $129,688 |
| LinzessLinaclotide | 103 | $127,102 |
| Bydureon BciseExenatide Microspheres | 54 | $88,965 |
| MounjaroTirzepatide | 58 | $87,780 |
| Diclofenac Sodium | 192 | $82,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $8,498 | $1,109,822836 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $1,233 | $617,872547 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,566 | $353,188195 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $7,267 | $333,025311 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $2,346 | $279,697299 claims |
| PfizerEliquis | $1,429 | $221,735205 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $4,145 | $129,688128 claims |
| AbbVieLinzess | $1,129 | $127,102103 claims |
| NovartisEntresto | $1,422 | $82,19452 claims |
| Johnson & JohnsonXarelto | $435 | $66,09651 claims |
| Astellas Pharma US IncMyrbetriq | $678 | $59,91648 claims |
| MerckJanuvia | $499 | $19,78322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.